Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/41761
Title: | Acute heart failure: current pharmacological treatment and perspectives | Authors: | Deniau, Benjamin Costanzo, Maria Rosa Sliwa, Karen Asakage, Ayu MULLENS, Wilfried Mebazaa, Alexandre |
Issue Date: | 2023 | Publisher: | OXFORD UNIV PRESS | Source: | EUROPEAN HEART JOURNAL, 44, p. 4634–4649 | Abstract: | Acute heart failure (AHF) represents the most frequent cause of unplanned hospital admission in patients older than 65 years. Symptoms and clinical signs of AHF (e.g. dyspnoea, orthopnoea, oedema, jugular vein distension, and variation of body weight) are mostly related to systemic venous congestion secondary to various mechanisms including extracellular fluids, increased ventricular filling pressures, and/or auto-transfusion of blood from the splanchnic into the pulmonary circulation. Thus, the initial management of AHF patients should be mostly based on decongestive therapies on admission followed, before discharge, by rapid implementation of guideline-directed oral medical therapies for heart failure. The therapeutic management of AHF requires the identification and rapid diagnosis of the disease, the diagnosis of the cause (or triggering factor), the evaluation of severity, the presence of comorbidities, and, finally, the initiation of a rapid treatment. The most recent guidelines from ESC and ACC/AHA/HFSA have provided updated recommendations on AHF management. Recommended pharmacological treatment for AHF includes diuretic therapy aiming to relieve congestion and achieve optimal fluid status, early and rapid initiation of oral therapies before discharge combined with a close follow-up. Non-pharmacological AHF management requires risk stratification in the emergency department and non-invasive ventilation in case of respiratory failure. Vasodilators should be considered as initial therapy in AHF precipitated by hypertension. On the background of recent large randomized clinical trials and international guidelines, this state-of-the-art review describes current pharmacological treatments and potential directions for future research in AHF. | Notes: | Mebazaa, A (corresponding author), Univ Hosp St Louis Lariboisiere, AP HP, Dept Anesthesia Burn & Crit Care, 2 rue Ambroise Pare, F-75010 Paris, France.; Mebazaa, A (corresponding author), Univ Paris Cite, INSERM, MASCOT, UMR S 942, Paris, France.; Mebazaa, A (corresponding author), Univ Paris Cite, Paris, France.; Mebazaa, A (corresponding author), FHU PROMICE, Paris, France. alexandre.mebazaa@aphp.fr |
Keywords: | Acute heart failure;Assessment of congestion;Decongestion therapy;Non-invasive ventilation;Guideline-directed medical therapy | Document URI: | http://hdl.handle.net/1942/41761 | ISSN: | 0195-668X | e-ISSN: | 1522-9645 | DOI: | 10.1093/eurheartj/ehad617 | ISI #: | 001085712200001 | Rights: | The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. Free access | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Acute heart failure_ current pharmacological treatment and perspectives.pdf | Published version | 1.06 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.